Literature DB >> 32320396

Drosophila NUAK functions with Starvin/BAG3 in autophagic protein turnover.

David Brooks1, Fawwaz Naeem1, Marta Stetsiv1, Samantha C Goetting1, Simranjot Bawa1, Nicole Green1, Cheryl Clark1, Arash Bashirullah2, Erika R Geisbrecht1.   

Abstract

The inability to remove protein aggregates in post-mitotic cells such as muscles or neurons is a cellular hallmark of aging cells and is a key factor in the initiation and progression of protein misfolding diseases. While protein aggregate disorders share common features, the molecular level events that culminate in abnormal protein accumulation cannot be explained by a single mechanism. Here we show that loss of the serine/threonine kinase NUAK causes cellular degeneration resulting from the incomplete clearance of protein aggregates in Drosophila larval muscles. In NUAK mutant muscles, regions that lack the myofibrillar proteins F-actin and Myosin heavy chain (MHC) instead contain damaged organelles and the accumulation of select proteins, including Filamin (Fil) and CryAB. NUAK biochemically and genetically interacts with Drosophila Starvin (Stv), the ortholog of mammalian Bcl-2-associated athanogene 3 (BAG3). Consistent with a known role for the co-chaperone BAG3 and the Heat shock cognate 71 kDa (HSC70)/HSPA8 ATPase in the autophagic clearance of proteins, RNA interference (RNAi) of Drosophila Stv, Hsc70-4, or autophagy-related 8a (Atg8a) all exhibit muscle degeneration and muscle contraction defects that phenocopy NUAK mutants. We further demonstrate that Fil is a target of NUAK kinase activity and abnormally accumulates upon loss of the BAG3-Hsc70-4 complex. In addition, Ubiquitin (Ub), ref(2)p/p62, and Atg8a are increased in regions of protein aggregation, consistent with a block in autophagy upon loss of NUAK. Collectively, our results establish a novel role for NUAK with the Stv-Hsc70-4 complex in the autophagic clearance of proteins that may eventually lead to treatment options for protein aggregate diseases.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32320396      PMCID: PMC7176095          DOI: 10.1371/journal.pgen.1008700

Source DB:  PubMed          Journal:  PLoS Genet        ISSN: 1553-7390            Impact factor:   5.917


Introduction

Proteins must fold into an intrinsic three dimensional structure to perform distinct cellular functions. Denatured or misfolded proteins can be refolded by chaperones or are subject to degradation by the ubiquitin-proteasome system (UPS) and/or the autophagosome-lysosome pathway (ALP) [1-3]. The accumulation of misfolded proteins upon genetic mutation or decreased chaperone function causes protein aggregates that are not effectively cleared by the UPS or the ALP. Environmental insults or aging may exacerbate this accumulation of misfolded proteins, resulting in disease and eventual cell death [4]. A specialized autophagy pathway, termed chaperone-assisted selective autophagy (CASA), has been verified in both Drosophila and mammalian systems [5-10]. The CASA complex includes BAG3 in concert with the chaperones HSC70/HSPA8 (HSP70 family), HSPB8 (small HSP family), and the ubiquitin (Ub) ligase CHIP/STUB1 [11]. CASA regulates the removal and degradation of Fil from the Z-disc in striated muscle or actin stress fibers in non-muscle cells [11-13]. The N-terminal actin-binding domain (ABD) in Fil is followed by multiple immunoglobulin (Ig)-like repeats which bind numerous proteins to link the internal cytoskeleton to the sarcolemma [14]. Tension exerted by contractile muscle tissue requires continuous folding and refolding of individual Ig-like domains in Fil, eventually damaging the ability of the protein to sense and transmit mechanical strain [11, 15]. The BAG3-HSC70 protein complex binds to the mechanosensor region (MSR) of Fil and upon detection of protein damage, CHIP ensures the addition of polyubiquitin (polyUb) moieties [12]. Rather than promoting delivery to the proteasome, these Ub chains instead recruit the autophagic Ub adapter protein p62/SQSTM1 [11]. p62 interacts with Atg8a/LC3 to induce autophagophore formation and the subsequent clearance of Fil through lysosomal degradation [16, 17]. Fil aggregates and a block in autophagosome-lysosome fusion are present in lysosomal associated membrane protein 2 (LAMP2)-deficient muscles, thus linking impaired autophagy to abnormal protein deposits [11, 18]. Drosophila NUAK encodes for a conserved serine/threonine kinase that is homologous to the mammalian kinases NUAK1/ARK5 and NUAK2/SNARK [19]. These proteins comprise a family of twelve AMP-activated protein kinase (AMPK)-related kinases (NUAK1 and 2, BRSK 1 and 2, QIK, QSK, SIK, MARK 1–4, and MELK) that share a conserved N-terminal kinase domain activated by the upstream liver kinase B1 (LKB1) [20]. NUAK1 and NUAK2 proteins are broadly expressed, but enriched in cardiac and skeletal muscle [21-24]. Muscle contraction and LKB1 phosphorylation can activate both NUAK proteins [19, 22]. NUAK2 activity is additionally stimulated by oxidative stress, AMP, and glucose deprivation in various cell types [22]. Interestingly, NUAK2 expression increases during muscle differentiation and in response to stress or in aging muscle tissue, whereas dominant-negative (DN)-NUAK2 induces atrophy [23]. Homozygous NUAK1 KO mice are embryonic lethal and <10% of NUAK2 homozygotes survive [25], precluding analysis of post-embryonic contributions. Because of this embryonic lethality, conditional NUAK1 KO mice were generated to examine muscle function [26, 27]. However, no change was observed in muscle mass or fiber size between control or muscle-specific NUAK1 KO mice, likely due to functional redundancy. The presence of single NUAK orthologs in worms (Unc-82) or flies (NUAK/CG43143) allows for the study of NUAK protein function without compensation from additional family members that may mask cellular roles. Unc-82 associates with Paramyosin and likely Myosin B to promote proper myofilament assembly in C. elegans [28, 29]. The kinase domain in Drosophila NUAK shares 61% identity and 80% similarity to human NUAK1 and NUAK2. In flies, RNAi knockdown of NUAK phenocopies weak Lkb1 defects in regulating cell polarity during ommatidial formation and actin cone formation in spermatogenesis [30, 31]. NUAK kinase targets or additional functions in other tissues have not been reported. Here we identify Drosophila NUAK as a key regulator of autophagic protein clearance in muscle tissue. NUAK physically interacts with and phosphorylates Fil [encoded by Drosophila cheerio (cher)]. NUAK also genetically and biochemically interacts with the Stv-Hsc-70-4 complex and Stv overexpression is sufficient to rescue NUAK-mediated muscle deterioration. The identification of Fil as a cargo protein that abnormally accumulates in muscle tissue deficient for NUAK, Stv, Hsc70-4, and Atg8a links protein aggregation to defects in autophagic disposal.

Results

NUAK mutants (NUAK-/-) exhibit a degenerative muscle phenotype

We and others have identified novel mutations that affect muscle structure or function using abnormal pupal morphology as a visual marker [32-35]. Contraction of body wall muscles during the larval to pupal transition results in a characteristic WT pupal case (), whereas the inability to contract muscles causes elongated pupae (). To identify additional regulators of muscle biology, we screened a collection of 566 EMS-induced pupal lethal mutations for abnormal pupal morphology [36]. Seven mutations in this collection exhibited an elongated and/or curved pupal phenotype. One of these mutations mapped to the previously characterized sallamus (sls) locus and encodes for the large muscle protein Titin, validating the functionality of our screening approach in identifying mutants that are defective in muscle structure and/or function. Deficiency (Df) mapping of the mutation in , originally designated l(3)17289, narrowed the region down to nine protein encoding genes within Df(3R)BCS479 (). Sequencing of messenger RNAs (mRNA) isolated from l(3)17289 homozygous mutants revealed a C→T transition resulting in a premature stop codon (AA829) in the uncharacterized gene CG43143 (hereafter referred to as NUAK) (). Gross level examination of third larval instar (L3) fillets revealed a dramatic loss of tissue integrity in muscles homozygous for the l(3)17289 alelle (NUAK-/-), primarily characterized by thinning or detached muscles (). Targeting of two independent RNAi lines in muscle tissue (mef2>NUAK RNAi) each decreased NUAK transcript levels by more than 50% and showed similar defects in muscle morphology (). Together, these data strongly suggest that NUAK functions in preventing muscle tissue degeneration.

NUAK mutants are defective in muscle structure and function.

(A,B) Representative pupal cases. (A) WT pupae exhibit a stereotypical size and shape with prominent anterior spiracles (asterisk). (B) Mutations in NUAK result in elongated pupae with shorter spiracles (double asterisks) and a failure in abdominal air bubble displacement (arrow). (C,D) Three hemisegments of L3 muscle pelts stained with phalloidin to visualize F-actin. (C) A regular pattern of somatic body wall muscles is apparent in WT fillets. (D) Drastic morphological defects, including thinner (carets) and detached (arrowhead) muscles are prevalent in NUAK-/-. (E) Box and whisker plot showing the axial ratios, or length (l) to width (w) proportions, of the indicated genotypes. Reductions in NUAK, either through mutations or RNAi knockdown, all exhibit a greater axial ratio compared to WT pupae (gray dashed line). Reintroduction of muscle-expressed NUAK rescues the elongated pupal phenotype back to WT. Rescue crosses were performed at 18°C (NUAK-/-, mef2>NUAK and mef2>NUAK), while 29°C was used to induce maximal RNAi knockdown (24B/+, 24B>GFP , 24B>NUAK ). Statistical values directly above each genotype are compared to WT (left panel) or 24B (right panel) control larvae. (F) Scatter plot depicting the locomotor ability of L3 larvae across agar plates. The motility of larvae deficient for NUAK is reduced, but can be restored with NUAK overexpression. All genotypes were reared at 18°C as rescue could be achieved at this temperature. Statistical values directly above each genotype are compared to WT control larvae. Mean +/- SD. (*, p<0.05; **, p<0.01; ***, p<0.005; ****p<0.001; n.s., not significant). We further confirmed NUAK as the causative gene for defective muscle function. First we measured pupal case length/width (axial) ratios to assess muscle contraction during the larval to pupal transition. The axial ratio value of WT pupae was approximately 3. In contrast, mutants homozygous for the l(3)17289 allele or this allele over the Df(3R)BSC479 deficiency showed an axial ratio greater than 4 (). Ubiquitous (da-Gal4) knockdown of NUAK using two independent RNAi hairpins phenocopied these increased pupal case axial ratios (). To determine if NUAK function is muscle autonomous, we induced NUAK RNAi with a Gal4 driver under control of the 24B (held out wings) muscle promoter and observed a failure of muscle contraction during the larval to pupal transition (). Reintroduction of full length NUAK cDNA into muscle tissue under control of the mef2 promoter rescued this elongated pupal phenotype in NUAK-/-, confirming that NUAK is indeed the causative gene for the observed phenotypes. In a second assay to evaluate the functional necessity of NUAK in muscle contraction, we monitored larval locomotion. WT L3 larvae traversed across an agar plate at an average velocity of 0.6 mm/sec (). The rate of NUAK-/- larvae was greatly reduced compared to WT or mef2 controls, but improved upon NUAK overexpression in muscle tissue. This muscle-specific rescue of NUAK in pupal body wall contraction and larval locomotion does not rule out a role for NUAK in neuromuscular transmission. To further explore this possibility, we reduced NUAK in either muscles or neurons and assessed muscle morphology and locomotion. Muscle-specific knockdown of NUAK showed both muscle degeneration and locomotion defects (), while this same decrease in the neuronal contribution of NUAK had no effect (). Muscle morphology was next examined from the onset of myogenesis to determine the temporal progression of degeneration that resulted in the dramatic phenotypes present at the end of larval development (). While all muscle groups were affected upon loss of NUAK, we chose to follow ventral longitudinal muscles 3 (VL3) and 4 (VL4) from stage 16 in embryogenesis through the L3 stage. VL3 and VL4 are part of the innermost group of VL muscles that span each abdominal segment () [37]. The addition and maturation of sarcomeres results in highly regular, repeated striations in second instar larval (L2) muscles () that persist into the L3 stage (). The overall pattern of embryonic muscles appeared normal upon loss of NUAK (). Muscle abnormalities were first observed in L1 individuals () and this cellular degeneration continued throughout the L2 () and L3 stages (), culminating in thinner muscles devoid of typical sarcomere patterning (white dotted lines).

Progressive muscle degeneration is prevalent upon a loss of NUAK.

(A-F) Visualization of muscles VL3 and VL4 (green) throughout embryonic and larval development. Muscle attachment sites at the hemisegment borders are denoted with yellow lines. (A,D) Two hemisegments of the embryonic musculature in stage 17 embryos are immunostained with anti-MHC. (B,C,E,F) Phalloidin-labeled WT or NUAK-/- larvae. (A) The normal muscle pattern in a WT embryo. (B,C) WT muscles are rectangular and increase in size from the L2 (B) to the L3 (C) stage. (D) The final pattern of muscles in homozygous NUAK-/- embryos appears WT. (E,F) Muscle defects, including a loss of sarcomeric patterning and thinning muscles (white dotted line) in NUAK-/- are apparent in L2 individuals (E) and progressively deteriorate during the L3 stage (F). Asterisks indicate affected muscles. (G) Scatter plot showing the length of individual VL3 muscles during larval development upon loss of NUAK. (H-N) Knockdown of NUAK via expression of a weaker RNAi line in muscle tissue (mef2>UAS-NUAK ). (H) Scatter plot reveals a decrease in locomotor ability upon NUAK RNAi compared to GFP RNAi controls. (I,J) Muscles VL3 and VL4 (green) are not affected in GFP RNAi control larvae (I), but exhibit variable defects upon NUAK RNAi knockdown (J, white dotted lines). Asterisks indicate affected muscles. (K,L) Scatter plots indicate that the length of VL3 muscles is not altered (K), but sarcomere number is increased, upon induction of NUAK RNAi (L). (M,N) One hemisegment of the larval musculature in mef2>UAS-NUAK larvae under fed (M) or growth-inhibited (N) conditions (n = 6 for each). The increase in abnormal phenotypes (*) when growth is stalled indicates that muscle use is the primary cause of tissue degeneration. Mean +/- SD. (****p<0.001; n.s., not significant).

NUAK-mediated muscle degeneration is independent of growth

Somatic body wall muscles undergo massive growth during larval development. To determine if NUAK-mediated muscle degeneration affects muscle size, we measured myofiber length throughout larval development. Both WT and NUAK-/- VL3 muscles were approximately the same length in the L1 stage, while NUAK-deficient muscles measured longer in L2 larvae (). This increase in muscle length was no longer apparent in NUAK-/- L3 muscles (), possibly due to the loss of sarcomere morphology coupled with severe tissue degeneration (). To further understand the cellular basis for differences in larval muscle length, we took advantage of the ability to modulate NUAK function using RNAi. While NUAK transcript levels were quantitatively similar after RNAi silencing of either NUAK RNAi line (), the functionally weaker UAS-NUAK RNAi #1 insertion showed fewer degenerating muscles, allowing us to quantitate length in muscles that retained sarcomeres. First, we confirmed that induction of NUAK RNAi in larval muscles using the mef2-Gal4 driver at 25°C reduced locomotor activity (). Next, we found that the overall length of VL3 muscles were not different between GFP RNAi control () or mef2>NUAK RNAi larvae (), demonstrating that partial loss of NUAK does not affect muscle length. However, there was an increase in sarcomere number upon reduction of NUAK (), suggesting that at least one function of NUAK may be to limit new sarcomere addition. Alterations in nutritional status can be used to probe growth requirements during larval development. Larvae deprived of food ~ 70 hours (hrs) after egg laying (AEL) are retarded in growth, but retain the ability to crawl and may survive to adulthood, although reduced in overall body size [38]. To determine if NUAK function is linked to muscle growth or muscle use, we removed NUAK-/- larvae from food ~70h AEL and monitored development. While most of the WT larvae generated small pupae, NUAK-/- larvae died within 24h. To circumvent this lethality due to loss of NUAK, we performed the same experiment with weak knockdown of NUAK in muscle tissue. NUAK RNAi muscles showed minor defects when reared on normal food (), while the severity of these muscle phenotypes were consistently increased upon starvation (). Here we conclude that the muscle defects in NUAK mutants are independent of growth, but likely linked to muscle use.

Regions devoid of myofibrillar material contain heterogeneous protein aggregates

The severe muscle degeneration in NUAK-/- precluded analysis of sarcomere number (). However, these defective muscles showed a range of additional phenotypes, including thinner myofibers (white carets in ; asterisks in ), occasional muscle detachment (white arrowhead in ), and a loss of sarcomeric patterning (dotted lines in ). Thin and detached muscles represented ~25% of the defects present in NUAK-/- muscles (). The most prevalent phenotype upon loss of NUAK corresponded to dark regions that lacked the typical F-actin sarcomere structure. While high magnification images revealed the stereotypical repeating pattern of sarcomeres in WT muscles (), this same examination of NUAK-/- muscle tissue in areas with aberrant sarcomeric patterning (dotted lines in ) failed to stain positive for F-actin structures (). This lack of phalloidin staining in NUAK-/- muscles could result from the complete absence of cellular material or a displacement of F-actin by other myofibrillar components. To distinguish between these two possibilities, we examined the ultrastructure of the L3 musculature using transmission electron microscopy (TEM). WT muscles showed evenly spaced sarcomeres with prominent Z-discs (indicated by double arrowhead in ). Loss of NUAK caused disintegration of Z-disc morphology and an overall disorganization of the repeated sarcomere pattern (note extended double arrowhead in ). Notably, areas within NUAK-/- muscles that lost sarcomere structures (brackets in ) instead contained a heterogeneous mixture of damaged organelles (black indented arrowhead in ) and electron-dense aggregates (black arrows in ), clearly illustrating that regions devoid of myofibrillar components are replaced with the abnormal accumulation of cellular material.

Myofibrillar material is replaced by damaged organelles and abnormal aggregates in NUAK-deficient muscles.

(A) Bar graph showing the relative percentage of phenotypes present in NUAK-/- muscles. (B,C) High magnification images of muscle tissue stained with phalloidin (green). (B) WT muscle shows a stereotypical pattern of sarcomeres with prominent Z-discs (white indented arrowheads). (C) F-actin labeled myofibrillar material is absent in large regions (white dotted outlines) upon loss of NUAK. (D-F) TEM micrographs of filleted L3 muscle tissue. (D) WT muscles reveal organized sarcomeres with prominent Z-discs and evenly spaced sarcomeres (double arrows). (E) Wider sarcomeres (double arrows), disintegration of Z-disc structures, and the accumulation of damaged organelles (brackets) are present in NUAK-/- muscle. (F) High magnification micrograph reveals mitochondria with abnormal cristae (black indented arrowhead) and electron-dense protein aggregates (black arrows). Mean +/- SEM. To confirm the identity of proteins that correspond to the electron-dense aggregates in NUAK-/- muscle tissue, we immunostained L3 larvae with antibodies that label thin filament, thick filament, or Z-disc proteins. The actin-binding protein Tropomyosin (TM) is a thin filament protein that overlaps with F-actin adjacent to the Z-disc (, Z-disc denoted by white indented arrowhead). In NUAK-/- muscles, TM was not present in regions that lacked phalloidin staining (, white dotted lines). Similar results were obtained for the thick filament protein Myosin heavy chain (MHC). Whereas MHC alternated with F-actin in a periodic pattern in both WT () or NUAK-/- (, white dotted lines) muscle tissue, there was no aberrant accumulation of MHC in other regions. Since TM and MHC did not accumulate in areas where sarcomeres were absent in NUAK-/- muscles, we next examined the localization of Z-disc proteins. Muscle LIM protein at 84B (Mlp84B) is found exclusively at the Z-disc in WT muscle () [33]. This Z-disc association was maintained in patterned regions within NUAK-/- muscle, but was absent in regions devoid of F-actin (, white dotted lines). In contrast, the Z-disc proteins CryAB and Fil exhibited a different pattern. Both CryAB () and Fil () are present at the Z-disc (white indented arrowhead) with a broader distribution across the sarcomere in WT muscle [39]. CryAB () and Fil () were present in filamentous-like aggregates (white arrows) in NUAK-/- muscle, strongly suggesting that specific proteins accumulate in regions that lack F-actin structures.

Select proteins accumulate in NUAK-/- muscles.

(A-J’) Protein localization of F-actin (green) and the indicated proteins (purple) in WT (A-E’) or NUAK-/- (F-J’) L3 muscle. All images are cropped and represent internal regions of intact muscles. (A-E’) The normal localization of the thin filament protein TM (A,A’), the thick filament protein MHC (B,B’), or the Z-disc protein Mlp84B (C,C’) across multiple sarcomeres are shown. Both CryAB (D,D’) and Fil (E,E’) exhibit a broader localization in muscle tissue. Z-discs indicated by the white indented arrows. (F-J’) TM (F,F’), MHC (G,G’) and Mlp84B (H,H’) are all absent from regions that lack F-actin (white dotted outlines). In contrast, both CryAB (I, I’) and Fil (J,J’) can be found as aggregates (white arrows) in regions lacking F-actin (white dotted outlines) in the absence of NUAK. (K-N”) (K) Box and whisker plot of pupal case axial ratios of the indicated genotypes. Independent mutation of two residues in the kinase domain fail to rescue muscle contraction. WT axial ratios values are indicated the gray dashed line. Statistical values directly above each genotype are compared to WT control larvae. (L-N”) Phalloidin-labeled muscles (green) exhibit NUAK-like muscle phenotypes (white dotted outline) and the accumulation of Fil (purple). Mean +/- SD. (*, p<0.05; **, p<0.01; ****p<0.001; n.s., not significant). Human NUAK1 has been shown to phosphorylate Myosin phosphatase target subunit 1 (MYPT) [40]. To determine if this catalytic activity is conserved in Drosophila NUAK, we generated transgenic flies with two independent kinase-dead mutations (K99R or E197K) [28, 41]. Recombination of these mutations into a NUAK-/- background failed to rescue muscle contraction during the larval to pupal transition (). Further analysis of the E197K mutation revealed muscle degeneration similar to those observed in NUAK mutants () with an accumulation of Fil in regions devoid of F-actin (, white dotted lines). These results show that NUAK kinase activity is important in preventing muscle degeneration and the abnormal accumulation of Fil protein. Control experiments were performed to confirm that the accumulation of select proteins upon loss of NUAK is indeed due to inherent defects inside each myofiber. First, intentional damage to WT muscles did not show an accumulation of Fil in regions lacking phalloidin staining ( indented arrowheads). Second, the sarcolemma was still intact in NUAK-/- muscles (), ruling out internal protein loss due to damaged membranes. In conclusion, our TEM and immunostaining analysis shows that loss of NUAK results in the selective accumulation of a subset of muscle proteins.

NUAK biochemically interacts with Stv/BAG3 and Fil

A role for NUAK in muscle degeneration and/or protein aggregation has not been reported. Therefore, we chose a yeast two-hybrid screening approach (Y2H) to gain an unbiased molecular understanding of NUAK function. Full length Drosophila NUAK (AA1- 1180) was cloned in-frame with the Gal4 DNA binding domain and this bait was utilized to screen a Drosophila L3 library. Three clones corresponding to Stv and twenty-nine clones encoding for Fil emerged as prey proteins. A clone for each (A-255 and A-105) was further selected for validation. After independent retransformation of both bait and prey vectors, we confirmed a direct, physical interaction between NUAK with Stv or Fil (). Analysis of Stv prey fragments that bind to NUAK reveal that the interaction domain encompasses amino acids 322–516, which includes the conserved BAG domain (). Ig domains 15–18 of Fil were found to interact with NUAK. Since phosphorylated forms of Filamin A and Filamin C have been identified in mammalian muscle tissue [42-44], we posited that Drosophila Fil may be a substrate for NUAK kinase activity. To test this possibility, we looked for differences in the relative migration of Fil protein after 2D gel analysis followed by Western blotting. Intriguingly, the migration pattern of Fil differed between WT and NUAK-/- samples. We identified four distinct spots corresponding to modified or unmodified forms of Fil (f1-f4) (). While the position of spots f3 and f4 appeared similar in WT and NUAK-/- muscle tissue, the prevalent f1 and f2 spots shifted towards a positive pI upon loss of NUAK, which we assume is due to loss of negatively-charged phosphate group(s) on Fil.

Stv/BAG-3 and Fil physically interact with NUAK.

(A) Confirmation of one-by-one Y2H interaction results using NUAK as a bait with Stv and Fil as prey proteins. The selective medium lacking tryptophan and leucine is used as a positive control to verify the presence of the bait and prey plasmids. Three independent yeast clones were streaked onto plates lacking histidine to verify NUAK protein interactions with Stv or Fil (blue boxes). (B) Schematic of Drosophila Stv and the C-terminal region of Fil isoforms (Ig domains 12–20). The orange bar represents the selected interaction domain of NUAK with the conserved BAG3 domain of Stv and Ig domains 15–18 in Fil. (C) 2D gel Western blot of WT or NUAK-/- muscle carcasses probed with anti-Fil. Two forms of phosphorylated Fil in WT muscle (f1 and f2) disappear upon loss of NUAK. A predominant spot likely corresponding to non-phosphorylated Fil (f3) is present in both WT and NUAK-/- muscle tissue, with f4 present as a possible minor form. We next wanted to confirm an in vivo role for the NUAK-Stv complex in muscle tissue to functionally verify our Y2H interaction. We leveraged the power of the temperature-dependent Gal4/UAS system [45] to develop a muscle-specific genetic interaction assay in which six muscles in each hemisegment [longitudinal lateral muscle 1 (LL1), lateral oblique 1 (LO1), VL1-4] were evaluated for muscle morphology defects. Muscles that were heterozygous for NUAK and a muscle Gal4 driver (NUAK+/-; mef2>+) appeared normal and show that a single WT copy of NUAK is sufficient to maintain L3 muscles (). At 25°C, a temperature with intermediate Gal4 expression, induction of the weaker NUAK RNAi construct (mef2>NUAK RNAi #1) resulted in morphological defects in ~40% of muscles analyzed (). However, this same reduction in NUAK mRNA levels in a heterozygous NUAK+/- background increased the percentage of affected muscles to nearly 100% (). Thus, a NUAK sensitized background was successfully established to evaluate genetic interactions between NUAK and stv.

NUAK and stv genetically interact in muscle tissue.

(A-E) Muscles LL1, LO1, and VL1-4 in one hemisegment of the L3 musculature stained for F-actin (green). NUAK +/-, mef2-Gal4 muscles appear WT at 25°C. (B) Weak muscle defects are prevalent upon muscle expression of UAS-NUAK alone. (C) This same reduction in NUAK transcript levels enhances muscle phenotypes in a heterozygous NUAK+/- background. (D,E) Weak perturbations in muscle morphology upon induction of UAS-stv alone (D) are enhanced upon removal of one copy of NUAK (E). (F) Scatter and bar plot depicting the percentage of muscle defects in the indicated genotypes. (G,H) Fil (purple) accumulates in regions lacking F-actin (green) in stv/stv mutants (G) or upon muscle-targeted expression of stv RNAi (H). (I) Box and whisker plot of the indicated genotypes. A decrease in stv using mutant alleles (stv/stv) or through the induction of two independent RNAi lines (UAS-stv or UAS-stv) both exhibit defects in muscle contraction, resulting in an extended pupal axial ratio. WT values are indicated by gray dashed line. Statistical values directly above each genotype are compared to WT control larvae. (J-M) F-actin-labeled VL3 muscle (green). Areas that lack phalloidin staining (white dotted outlines) in NUAK-/- (J) are rescued upon the reintroduction of full length NUAK cDNA in muscle tissue (NUAK-/-; mef2>NUAK) (K). Expression of a V5-tagged Stv protein rescues NUAK-/- phenotypes (L), while overexpression of CG14207-V5 fails to rescue (M). (N) Bar graph depicting rescue results. Mean +/- SEM. (**, p<0.01; ***, p<0.005; ****, p<0.001; n.s., not significant). Two independent stv RNAi lines that reduced stv transcript levels more than 50% () were induced under control of the mef2 promoter. Each line showed variable defects ranging from 20–50% of muscles affected in each hemisegment (). A representative example of the morphological phenotypes seen upon muscle-specific expression of the weaker stv RNAi line #1 is shown in . Knockdown of this same stv RNAi line in a heterozygous NUAK+/- background enhanced the percentage of defective muscles (). Note that induction of the stronger stv RNAi line #2 did not significantly enhance muscle defects in NUAK+/- larvae (), likely because knockdown of stv transcript was already reduced enough to cause severe muscle defects. No muscle abnormalities were observed upon induction of an exogenously supplied GFP RNAi in a NUAK-sensitized background (similar to the NUAK+/-; mef2>+ control) (). These data demonstrate a genetic interaction between NUAK and stv in muscle tissue, further supporting our Y2H interaction data. Individuals homozygous for stv are lethal before the end of the first larval instar (L1) stage [11, 46]. To examine a role for Stv in L3 muscle maintenance, we examined the partially lethal P-element insertion allele stv in combination with stv (stv/stv). Muscles of this genotype recapitulated NUAK-/- phenotypes, including the accumulation of Fil in regions devoid of F-actin (dotted lines in ). We further confirmed NUAK-like muscle and Fil aggregation phenotypes upon muscle-targeted expression of stv RNAi (). These morphological defects correlate with muscle dysfunction as stv mutants or stv RNAi knockdown larvae failed to contract their musculature during pupal morphogenesis. The pupal axial ratio for all genotypes with reduced stv levels is significantly longer than WT or mef2>+ driver controls (). Thus, partial loss of Stv using hypomorphic allelic combinations or RNAi techniques phenocopies NUAK muscle defects, further supporting our conclusion that NUAK and stv genetically interact. We next utilized a genetic overexpression approach to determine the relationship between NUAK and stv. Regions lacking F-actin in NUAK-/- muscle () were rescued to WT muscle morphology upon expression of a full length NUAK cDNA (). Similar results were observed upon overexpression of a V5-tagged version of Stv (), while induction of an independently tagged chaperone (CG14207-V5) failed to ameliorate these phenotypic abnormalities (). Thus, Stv functions parallel to or downstream of NUAK. To test if NUAK can function downstream of Stv, we performed a reciprocal type of rescue experiment. While over-expression of NUAK is sufficient to rescue muscle defects in a NUAK RNAi background, this same NUAK over-expression failed to rescue stv-mediated muscle defects (). These data collectively show that NUAK and Stv not only biochemically interact, but also function within the same genetic pathway to prevent muscle degeneration.

NUAK and Stv are required for the autophagic degradation of Fil

Stv is the Drosophila ortholog of mammalian BAG3, a molecular co-chaperone implicated in numerous biological processes, including apoptosis, development, cytoskeletal dynamics, and autophagy [16, 47–49]. Using full length Stv as a bait, we again screened an L3 library using the Y2H approach. High confidence interactions are listed in . Two clones of NUAK were identified, further verifying the Stv-NUAK physical interaction. The highest number of clones encoded for Heat shock protein cognate 4 (Hsc70-4). BAG3 is well established as a nucleotide-exchange factor for the HSC70 ATPase that promotes the release of ADP and associated client proteins [50-52]. To confirm the Stv-NUAK and Stv-Hsc70-4 interactions in muscle tissue, we postulated that a heterozygous stv background may be useful for detecting genetic interactions. Larval muscles heterozygous for the stv allele [46] recombined with mef2-Gal4 (stv+/-, mef2>) alone or crossed to GFP RNAi appeared normal (). Consistent with our data showing that NUAK and stv function together (), muscle defects were increased when the mRNA levels of NUAK were reduced in larvae containing a single copy of stv (). We next examined if RNAi knockdown of Hsc70-4 also enhanced muscle phenotypes in a heterozygous stv+/- background. However, induction of Hsc70-4 RNAi alone resulted in 100% defective muscles () and larvae did not survive until the L3 stage in a sensitized stv background (). Even at the low temperature of 18°C, mef2>Hsc70-4 RNAi individuals failed to contract their body wall muscles during the larval to pupal transition () and showed Fil accumulation in regions lacking F-actin (). Here we confirm that Hsc70-4 is a binding partner of Stv and conclude that a decrease of Hsc70-4 in muscle phenocopies the aggregation and cellular degeneration defects in NUAK or stv mutants.

Hsc70-4 is required to prevent protein aggregation.

(A) Table showing prey proteins that interact with Stv in a Y2H screen. SID = selected interaction domain. (B) Scatter and bar plot demonstrating a genetic interaction between stv and NUAK. RNAi knockdown of NUAK or stv further enhances the percentage of muscle defects in a heterozygous stv genetic background (stv +/-). (C,D) Pupal case morphology. (C) Flies that contain an insertion of the mef2-Gal4 driver appear WT. (D) RNAi knockdown of Hsc70-4 causes an elongated pupal case, defective spiracles (double asterisks) and a failure to displace the abdominal air bubble (arrow) due to defective muscle contraction. (E) Quantification of pupal axial ratios of the indicated genotypes clearly show that decreased Hsc70-4 mRNA levels exhibit muscle contraction defects compared to WT or mef2 controls (gray dashed line). (F) Muscles of the genotype mef2>Hsc70-4 RNAi show accumulation of Fil (purple) in areas that lack F-actin (green). Mean +/- SEM. (**, p<0.01; ****, p<0.001; n.s., not significant). Aggregation-prone client proteins, such as Fil, are recognized by a multi-chaperone complex consisting of Stv/BAG3 and Hsc70-4/Hsc70 to induce ubiquitination and p62/SQSTM1 recruitment [6, 7, 16, 47, 49]. Because Fil abnormally accumulates in NUAK-/- and stv-/- muscle tissue, we hypothesized that both Ub and p62 may also associate in these regions. Antibodies that detect either Ub or p62 moieties were utilized to examine their distribution in WT or mutant muscle tissue. Puncta corresponding to Ub (, white arrowhead) were occasionally present in WT muscle, but more numerous in NUAK-/- () or stv-/- () muscle tissue. Similarly, p62(+) puncta were observed at low numbers in normal muscle (), but accumulated in regions lacking F-actin in NUAK-/- () or stv-/- (). This increased number of p62 puncta strongly suggests that autophagy is impeded upon loss of NUAK as has been reported for BAG3 [6, 16, 49]. Indeed, Western blot analysis confirmed that the overall levels of p62 were elevated in NUAK or stv mutant larvae (). Hence, we conclude that a nonfunctional NUAK-Stv complex blocks autophagic protein degradation, with a corresponding accumulation of Ub and p62.

Autophagy is blocked upon loss of the NUAK-Stv complex.

(A-C,E-G) Anti-Ub (A-C) or anti-p62 (E-G) immunostaining (purple) in L3 muscle tissue (green, F-actin). (A) Ub-(+) puncta (white arrowheads) are occasionally present in WT muscle. (B,C) Puncta that stain positive for Ub are clustered in areas of the muscle where F-actin is excluded (white dotted outlines) in NUAK-/- (B) or stv-/- (C). (D) Scatter plot depicting the number of Ub(+) puncta/20 um2. (E) Similar to Ub, puncta corresponding to p62 (white arrowheads) are found in normal muscle tissue. (F,G) p62(+) puncta are present in greater numbers upon loss of NUAK (F) or Stv (G). (H) Quantitation of p62(+) puncta/20 um2 depicted by a scatter plot. (I) Western blot of whole L3 larvae reveals a block in autophagy indicated by elevated p62 protein levels in NUAK or stv mutants. ATP5α is used as a loading control. Bar graph depicts the ratio of p62/ ATP5α intensity in the indicated genotypes. N = 3. (Mean +/- SEM. (*, p<0.05). Mean +/- SEM. (****, p<0.001). While there is an increase in the number of Ub puncta, the location of these Ub molecules do not fully recapitulate the abnormal pattern of Fil immunostaining in NUAK () or stv () mutants. Thus, we decided to compare Fil and Ub distribution in small regions that begin to show muscle deterioration (initiation) with larger areas in which the accumulation of select proteins has already occurred (aggregation). Puncta that stain positive for both Ub and Fil (white indented arrowheads) were abundant in areas just beginning to show changes in muscle morphology upon a reduction in NUAK (), Stv (), or Hsc70-4 (). However, in large regions that exhibit atypical Fil accumulation, only a subset of Fil protein was decorated with Ub (white indented arrowheads) upon perturbation of NUAK (), Stv (), or Hsc70-4 (). These similar patterns of Fil and Ub colocalization suggest a common mechanism whereby Fil molecules are initially marked by poly-Ub and a failure to clear these Fil-Ub complexes results in heterogeneous aggregate formation.

Ub distribution changes during aggregate accumulation.

(A-F) Fil (blue) and Ub (purple) immunostaining in L3 muscles in the early (A-C’) or late (D-F’) stages of aggregate accumulation. A decrease in NUAK (A,A’), Stv (B,B’), or Hsc70-4 (C,C’) results in small regions of muscle tissue that begin to accumulate puncta decorated with Fil and Ub puncta (white indented arrowheads). In large areas of aggregate accumulation in NUAK-/- (D,D’) and stv-/- (E,E’) mutants or upon Hsc70-4 RNAi knockdown (F,F’), the co-localization of Ub(+) puncta with Fil protein (white indented arrowheads) is decreased. The white boxed regions in A-F are enlarged in A—F’. Multiple pieces of evidence thus far suggest that protein aggregates accumulate in NUAK-/-muscle tissue: (1) TEM analysis shows that electron-dense protein aggregates replace myofibrillar material; (2) heterogeneous aggregate-like structures of Fil and CryAB are observed by immunofluorescence in regions that lack F-actin; and (3) there is an increased number of puncta corresponding to Ub that colocalizes with Fil protein. To show that Fil is indeed present in insoluble aggregates, we performed biochemical fractionation on WT or NUAK-/- muscle carcasses followed by Western blotting. Fil was found in the RIPA and Urea soluble fractions of both WT and NUAK-/- lysates in approximately equal amounts (). However, upon loss of NUAK, large amounts of insoluble Fil were present at the expected molecular weight (single asterisk) and in a high molecular weight species that failed to enter the gel (double asterisk). Aggregates linked to K63-based ubiquitin chains are typically found in insoluble fractions when autophagy is blocked [2, 53, 54]. Using an antibody specific for K63-linked ubiquitin chains, we confirmed enrichment of this poly-ubiquitinated species in the insoluble fractions of NUAK-/-muscle tissue (). Notably, a large amount of K63-linked proteins was also present at the top of the gel (double asterisk), similar to that for Fil. These experiments importantly demonstrate that Fil abnormally accumulates in insoluble aggregates.

Loss of NUAK results in the insoluble accumulation of Fil and K63-linked Ub.

(A,B) Western blots probed for Fil (A) or K63-linked Ub chains (B) after fractionation of WT or NUAK-/- L3 muscle carcasses into soluble or insoluble fractions. (A) Fil protein levels are similar in RIPA or Urea-soluble fractions, but preferentially increased in the pellet (solubilized by SDS, single asterisk). A substantial portion of aggregated Fil protein did not migrate into the gel (double asterisks). Densiometric quantitation of Fil protein levels (single asterisk) reveals ~5-fold increase in Fil protein levels upon loss of NUAK. (B) Poly-Ub chains that contain K63 linkages broadly accumulate in the insoluble fractions of NUAK-/-. Similar to Fil, a portion of K63-linked proteins accumulate in the top of the SDS-PAGE gel (double asterisk). The loading control ATP5α is largely soluble, but also present in Urea and SDS-soluble fractions. HisH3 was used to confirm insoluble loading. The core autophagy protein Atg8a/LC3 is recruited by p62 and is required for the biogenesis of autophagosomal membranes for eventual protein disposal in the lysosome [55, 56]. Drosophila possesses two Atg genes, Atg8a and Atg8b. Atg8b expression is high is adult testes and weakly expressed in larval fat body tissue [57, 58]. Thus, we next examined a genetic role for the ubiquitously expressed Atg8a in preserving muscle function. Muscle-specific RNAi silencing of Atg8a impaired muscle contraction during the larval to pupal transition (). The axial ratio of these mef2>Atg8a RNAi pupal cases was enhanced upon removal of a single copy of NUAK or stv. As expected, the heterozygous NUAK+/-; mef2>+ or stv+/-; mef2>+ pupal cases were similar to mef2-Gal4 or mef2>GFP RNAi controls. mef2>Atg8a RNAi muscles showed thinning muscles with regions devoid of F-actin (). The penetrance of these muscle defects (~60% in mef2>Atg8a RNAi alone) remained the same in the NUAK+/- background, but was enhanced to almost 100% in a heterozygous stv background ().

Atg8a genetically interacts with NUAK and stv and is required to prevent protein aggregation.

(A) Axial ratios as a measure of muscle contraction are represented by a box and whisker plot. Gray dashed line indicates WT and control values. Statistical values directly above each genotype are compared to WT control larvae. (B) A grouped column plot shows the relative severity of muscle aggregation defects in Atg8a RNAi alone that are enhanced upon removal of one copy of stv. Regions that showed initiation of abnormal muscle morphology were considered mild defects and large aggregate holes were classified as severe defects. (C-F’) Ub (purple) or Fil (blue) immunostaining in mef>Atg8aRNAi muscle tissue labeled with phalloidin (green). (C,D) In small regions where F-actin is displaced (asterisks), Ub accumulation is observed. (E-F’) In larger regions where F-actin is missing, Ub puncta can be found decorating Fil protein aggregates (white indented arrowheads). (G-H’) Puncta corresponding to Atg8a (purple) accumulate in regions lacking F-actin (asterisks). Atg8a puncta detected by immunostaining (G,G’) or visualized with a GFP fusion protein (H,H’) can be found in ring-like structures (insets). (I-J’) Lamp1-GFP puncta (purple) are observed in the perinuclear region in WT muscle tissue, but cannot be found in regions lacking F-actin upon loss of NUAK (J,J’). Mean +/- SEM. (****, p<0.001; not significant). Next we assessed Ub or Fil distribution in muscles with reduced Atg8a. Ub (+) puncta were present in regions starting to lose normal F-actin morphology (, asterisks). In large aggregate regions, we observed Fil accumulation decorated with Ub protein ( white indented arrowheads). Atg8a protein, assayed by immunostaining () or through visualization of an Atg8a-GFP fusion protein (), was confirmed in regions lacking F-actin (asterisks). Moreover, some of these Atg8a(+) puncta appeared to be organized in ring-like structures, indicative of autophagosome formation (inset in ). Since the fusion of autophagosomes with lysosomes is required for cargo clearance, we next assessed whether lysosomes were present in aggregate regions. Visualization of lysosomes with Lamp1-GFP revealed a normal perinuclear accumulation in WT muscle (). However, Lamp1-GFP was never observed in regions of aggregate accumulation upon loss of NUAK ( These results suggest that Atg8a is recruited to form autophagosomes, but a failure to undergo lysosomal fusion prevents client protein turnover in NUAK-/- muscle tissue.

Discussion

Here we identify a novel protein aggregation phenotype in NUAK-/- muscle tissue that directly impacts sarcomere morphology and contractile function. Our data conclusively show that NUAK phosphorylates Fil and functions with Stv/BAG3 in autophagy-mediated protein clearance. The additional requirement of the HSC70 family member Hsc70-4/HSPA8 with Stv further substantiates a role for these proteins in autophagic protein turnover.

NUAK regulation of myofilament and cytoskeletal proteins

Prior to our study, few substrates of NUAK kinase activity had been uncovered. One of these is Myosin phosphatase targeting-1 (MYPT1), a regulatory subunit of myosin light-chain phosphatase [40]. We tested two Drosophila regulatory subunits, MYPT75D and Myosin binding subunit (Mbs) [59, 60] in our NUAK sensitized genetic assay and failed to observe protein aggregation and/or muscle degeneration. While negative, this data nevertheless argues that this family of phosphatases likely does not function with NUAK in muscle tissue. Since the mammalian NUAK1-MYPT1 interaction was identified in vitro and further validated in HEK293 cells, NUAK likely has cell and tissue-specific targets that regulate diverse biological outputs. Based upon our discovery of Fil as a novel NUAK substrate (), we envision two scenarios that are not mutually exclusive to explain the molecular function of NUAK in preventing protein aggregation. First, the increase in sarcomere number upon muscle-specific NUAK RNAi () suggests that at least one role of NUAK may be to negatively regulate the addition of proteins (such as Fil) into sarcomeres. This data is consistent with studies that show C. elegans Unc-82 regulates myofilament assembly [28, 29]. Notably, one key feature of the misincorporated proteins in unc-82 mutants is their inclusion into aggregate-like structures, similar to the accumulation of Fil and CryAB in NUAK-/- muscles. An additional, or alternative possibility, is that NUAK phosphorylates unfolded or ‘damaged’ Fil for removal from the sarcomere, thereby triggering the Stv-Hsc70-4 complex to promote autophagic turnover. Thus, proteins such as Fil that fail to get incorporated into sarcomeres and/or sustain damage due to repeated rounds of tension-induced muscle contraction, may destabilize myofilament architecture and trigger abnormal protein aggregation.

The NUAK-BAG3 pathway

In both contractile muscle tissue and in adherent cells subjected to mechanical force, BAG3 acts as a hub to coordinate Fil-induced tension-sensing and autophagosome formation [6, 7, 16, 47]. The MSR of Fil is comprised of Ig repeats whose conformational transitions between open and closed states dictate differential protein-protein interactions and biological outputs [11, 61, 62]. While the chaperones Hsc70/HSPA8 and HSPB8 weakly bind to the MSR of Fil, this biochemical interaction is greatly enhanced in the presence of BAG3 [12]. Interestingly, BAG3 interacts with Ig repeats 19–21 in the MSR, while the selected interaction domain of NUAK with Fil comprises Ig repeats 15–18 (). These data suggest that NUAK and Stv each bind to a separate region of the MSR in Fil. It remains to be determined if NUAK-mediated phosphorylation is a prerequisite for the removal of damaged Fil protein by BAG3 [10, 11]. Our rescue results suggest that this phosphorylation event is not required as Stv overexpression alleviates protein aggregation and muscle degeneration upon a loss of NUAK (). An alternative possibility is that this excess Stv protein is present in sufficient amounts to interact with Fil and overcome the necessity for phosphorylation by NUAK. The inability of NUAK overexpression to restore muscle defects due to knockdown of Stv, Hsc70-4, or Atg8a () suggests that NUAK functions upstream or parallel to this pathway. It seems likely that NUAK has additional target substrates for kinase activity that may regulate autophagic protein clearance in muscle tissue. Recent studies demonstrate that increased autophagic degradation of Fil by BAG3 also induces fil transcription as a compensatory mechanism to ensure steady-state Fil levels. Thus, we tested whether loss of NUAK or Stv alters gene expression upon a block in protein clearance. While the mRNA levels of cher, CryAB, Hsc70-4, or Atg8a were not altered in NUAK or stv mutants, there was a large increase in p62 transcripts (). Thus, this increase in p62 mRNA synthesis may contribute to the elevated p62 protein levels observed upon loss of NUAK or Stv as multiple stress conditions increase p62 transcription, including proteasome inhibition, starvation and atrophic muscle conditions [63, 64]. Data that support a role for an autophagic block include the localization of p62 and Atg8a to regions of protein aggregation.

Model for NUAK function

We propose a model for NUAK that incorporates our new findings with existing roles for BAG3 (). Fil and CryAB are physically associated at the Z-disc in Drosophila larval muscle [39]. The phosphorylation of Fil by NUAK may control the incorporation of Fil into the Z-disc during myofibril assembly and/or may be required for the disposal of damaged Fil protein. BAG3 and chaperones such as Hsc70/HSPA8 are thought to monitor the MSR of Fil to detect force-induced damage and to promote the addition of K63-linked polyUb chains [6, 7, 16, 47]. Recruitment of the ubiquitin autophagic adapter p62/SQSTM1 induces autophagosome initiation through the accumulation of Atg8a. Eventual fusion of these autophagosomes with lysosomes promotes protein client complex destruction.

Model for NUAK function.

(A) Autophagic protein clearance of Fil in WT muscle tissue. NUAK phosphorylates Fil either for incorporation into the Z-disc (1) and/or upon protein damage due to folding and unfolding of the protein (2). CryAB is normally bound to Fil at the Z-disc and the Stv-Hsc70-4 protein complex detects damaged Fil protein. The addition of K63-linked polyubiquitin chains on Fil recruits p62/SQSTM1 and Atg8a for autophagosome biogenesis. Autophagosomes fuse with lysosomes to form the autolyosome for eventual protein degradation. (B) Fil phosphorylation is lost in NUAK-/-. Unincorporated and/or damaged Fil protein at the Z-disc bound to CryAB. PolyUb, p62, and Atg8a proteins are still recruited to Fil-CryAB complexes. The absence of lysosomes in regions of protein accumulation prevents autophagic protein clearance. Upon loss of NUAK (), excess Fil protein that fails to be incorporated into the Z-disc and/or is damaged due to tension-induced muscle contraction begins to accumulate near the Z-disc. The presence of CryAB in Fil-like aggregates may be due to the normal association of CryAB with Fil at the Z-disc, either to monitor Fil protein damage, or to prevent protein aggregation [65-67]. It is interesting that while both Fil and CryAB contain actin-binding domains [39], these associations are lost in NUAK-/- muscle tissue as F-actin is displaced from regions of Fil-CryAB accumulation. At this point we cannot determine if NUAK preferentially binds to the short (~90kD) and/or long (~240 kD) Fil isoforms since the mapped interaction domains (Ig domains 15–18) are present in both isoforms. In the initial stages of aggregate formation, nearly all Fil puncta are decorated with Ub. We hypothesize that the observed decrease in Ub-Fil colocalization in large regions of aggregate formation may be due to intrinsic properties of aggregation-prone proteins whereby protein misfolding triggers aggregation of Fil with itself and other proteins [68]. The accumulation of p62 and circular structures that stain positive for Atg8a in regions of Fil accumulation demonstrate that the autophagosome machinery is recruited to BAG3-client complexes. The absence of lysosomes in these aggregate regions suggest that either fusion and/or transport to sites of degradation are compromised. CASA-mediated autophagy via the BAG3-client complex includes Hsc70-4/HSPA8, HSPB8, and the E3 ligase CHIP/STUB1, the latter of which ubiquitinates Fil for the subsequent recruitment of p62 to initiate autophagosome formation [11]. However, fibroblasts deficient for CHIP are not defective in autophagy and mice or flies lacking CHIP/STUB1 are viable [69, 70]. A failure to enhance protein aggregation defects upon CHIP RNAi knockdown in our sensitized NUAK+/- or stv+/- backgrounds suggests that additional Ub ligases cooperate with the Stv/BAG3 complex to remove damaged proteins (). Future studies will also determine which Drosophila protein is the equivalent of HSPB8 since we did not observe genetic interactions with putative CG14207 or Hsp67Bc RNAi lines (). This negative data does not rule out the possibility that protein levels are not reduced enough to see phenotypes upon RNAi induction or possible functional redundancy exists between CG14207 and Hsp67Bc.

Connections to protein aggregation disease

An interesting hallmark of protein aggregate diseases is the accumulation of specific proteins in affected cells or tissues. Thus, proteins susceptible to aggregation in vivo may possess specific structural characteristics or shared biological functions. This latter feature is evident in a group of protein aggregate diseases termed myofibrillar myopathies (MFM). Laser microdissection of aggregates from normal or affected muscles reveal specificity in the types of proteins that accumulate in patients afflicted with MFMs [71-73]. Common proteins present in these aggregates include Filamin C (FILC), αB-crystallin (CRYAB), BAG3, and Desmin (DES), among others. The inability of MFM patients to clear these aggregates results in myofibrillar degeneration and a decline in muscle function [74-80]. Interestingly, mutations in Drosophila NUAK phenocopy both structural and functional deficits observed in MFM patients, including Fil and CryAB accumulation, muscle degeneration, and locomotor defects. The discovery of cellular degeneration and protein aggregation in muscle tissue upon loss of the single fly NUAK ortholog highlights the power of Drosophila as a model. Future studies will focus on identifying kinase targets of NUAK and defining additional proteins that function in NUAK and stv-mediated autophagy for the eventual development of therapeutic targets to treat MFMs and other protein aggregate diseases.

Materials and methods

Drosophila stocks and growth conditions

Stocks

Drosophila stocks were obtained from the Bloomington (BL) Drosophila Stock Center (BDSC), the Vienna Drosophila Resource Center (VDRC), or the Kyoto Drosophila Genetic Resource Center (DGRC). The NUAK allele was isolated in an EMS screen [36] and analyzed over the deficiency stock Df(3R)BSC479 (BL24983). Other mutant alleles used in experiments were stv/TM6, Tb (a gift from Jörg Höhfeld) [11] and stv/TM3, Sb (BL11501). The following Gal4 lines were used to direct tissue-specific expression: da-Gal4 (originally BL37291 outcrossed ten times to w to remove background lethal mutations), elav-Gal4 (BL458), mef2-Gal4 (BL27390), and 24B-Gal4 (BL1767). RNAi lines used to knockdown transcript levels: UAS-NUAK RNAi #1 (TRiP.JF02162, BL31885), UAS-NUAK RNAi #2 (TRiP.GL00066, BL35194), UAS-stv RNAi #1 (TRiP.HMJ02221, BL42564), UAS-stv RNAi #2 (GD10796, VDRC34408), UAS-Hsc70-4 RNAi (TRiP.HMJ21529, BL54810), and UAS-Atg8a RNAi (GD4654, VDRC43097). RNAi lines used to knockdown transcript levels in Supplemental Figures: UAS-CHIP RNAi #1 (KK108451, VDRC107447), UAS-CHIP RNAi #2 (GD10538, VDRC34124), UAS-CG14207 RNAi (TRiP.HMC05590, BL64571), UAS-Hsp67Bc RNAi #1 (TRiP.HMS02440, BL42607), UAS-Hsp67Bc RNAi #2 (KK103547, VDRC103974), and UAS-cher RNAi (KK107518, VDRC107451). Fly stocks containing GFP fusion proteins were UAS-Atg8a-GFP (BL51656) and Lamp1-GFP (CPTI001775, DGRC115240). UAS-stv-V5 and UAS-CG14207-V5 were a gift from Harm Kampinga [81]. Mutant alleles and lethal transgenes were maintained over the appropriate balancer chromosome: Cyo, Tb (II), or TM6, Tb (III). Homozygous mutant larvae were chosen by selection against the Tb marker.

Rearing conditions

Flies were raised on standard cornmeal medium at 25°C unless otherwise specified. w was used as the WT control. All temperature-dependent crosses to analyze GAL4/UAS expression were performed at 29°C unless specified in the Figure legends. For starvation assay, larvae were removed from normal food at ~70 AEL and transferred to agar plates with a moist Kimwipe to prevent desiccation. Larvae that survived were dissected about 4 days later and stained with phalloidin.

Mapping and sequencing of NUAK mutants

Mapping

Pupal lethal lines isolated from a previously described EMS screen [36] that exhibited elongated pupal cases were crossed to third chromosome deficiency stocks (n = 177) obtained from the BDSC. The progeny of each cross were screened for pupal lethality and extended pupal case morphology. The l(3)17289 allele failed to complement Df(3R)ED5474 (BL9082). Verification with additional overlapping Df stocks narrowed down the cytological region to 86A3 to 86B1.

Sequencing

Homozygous mutant l(3)17289 L3 individuals were washed with 0.7% NaCl/0.04% Triton X-100 and thoroughly rinsed with ultrapure water. After homogenization, total RNA was extracted and purified using the RNeasy mini kit (Qiagen, Germantown, MD). Synthesis of cDNA was performed using the qScript XLT cDNA SuperMix kit (Quanta Biosciences, Beverly, MA). RT-PCR was performed using Promega GoTaq Flexi (Madison, WI) with NUAK_seq_forward 5’-TCATCGAACCGCAAGCTAC and NUAK_seq_reverse 5’- GTCCTCCTCGTTGGAGCTTT. Sanger sequencing was performed by GeneWiz using the following primer: 5’- GCTGCAGAGGGACCTACG.

Mutagenesis and the creation of transgenic flies

Clone FI03914 corresponding to NUAK-RD was obtained from the Drosophila Genomics Resource Center (DGRC). The entirety of this NUAK open reading frame (ORF) was PCR amplified with the forward primer 5’-CACCATGGTGATAAGCAAACCCGATGG and the reverse primer 5’-CTACTGATCTAGGTATTTACTCTTTATTC. This fragment was inserted into the Gateway pENTR/D-TOPO vector (Invitrogen) and recombined into the pTW destination plasmid (DGRC) using standard procedures to generate UAS-NUAK. pENTR/D-TOPO_NUAK was used as a template to introduce the K99R and E197K mutations using the QuikChange II XL Site-directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA). Primer sequences used were: NUAK_K99R forward 5’-TGCACTTCTTGATGGTTCTGATAGCCACCTCCTGG; NUAK_K99R reverse 5’-CCAGGAGGTGGCTATCAGAACCATCAAGAAGTGC; NUAK_E197K forward 5’- CGCGATCTCAAGCTGAAGAACATCCTGCTGG; NUAK_E197K reverse 5’- CCAGCAGGATGTTCTTCAGCTTGAGATCGCG. These mutagenized sequences were put into the pTW destination plasmid to generate UAS_NUAK_K99R and UAS_NUAK_E197K. All constructs were sequence verified and injected by Genetic Services, Inc. for the creation of transgenic flies.

Immunostaining

Wandering L3 larvae were dissected to isolate muscle fillets and fixed in 4% formaldehyde as described [32, 34, 82]. Tissues were stained with the following primary antibodies: mouse anti-TM (1:50, Babraham Institute, Cambridge, UK), mouse anti-MHC (1:500, Susan Abmayr) [83], rabbit anti-Mlp84B (1:50, Kathleen Clark) [33], rabbit anti-Fil (1:300, Lynn Cooley) [84], rat anti-CryAB (1:400, Teresa Jagla) [39], mouse anti-Ub (1:300, Enzo Life Sciences, Farmingdale, NY), and rabbit anti-ref(2)p (1:200, Abcam, Cambridge, MA), anti-Atg8a (1:200, Millipore, Burlington, MA), and anti-Perl (1:500, Stephan Baumgartner) ([85], 1:2000). Amino acids 611–838 of Cher_PB were used as an antigen to immunize rabbits (Bosterbio, Pleasanton, CA). This antibody was used at 1:200 for immunostaining (). Fluorescence was detected using the following secondary antibodies: Alexa Flour anti-mouse 488, Alexa Flour anti-rabbit 488, or Alexa Flour anti-rat 488 (1:400, Molecular Probes, Eugene, OR). F-actin was labeled with phalloidin 488, 594, or 647 (1:400, Molecular Probes, Eugene, OR). Images were captured using a Zeiss 700 confocal microscope. Image processing and analysis was performed using a combination of Zen Black (Zeiss), ImageJ (NIH), and Adobe Photoshop. All images taken at 4, 10x, or 20x are displayed as maximum intensity projections. Data acquisition at increased magnifications (40x or 63x) are presented a single plane confocal micrographs.

Transmission electron microscopy

Drosophila L3 larvae were filleted and fixed overnight in 1x Trump’s fixative (4% formaldehyde/1% glutaraldehyde in phosphate buffer) as in [86]. Fillets were processed with osmium tetroxide and put through a graded alcohol dehydration series before embedding in Spurr resin. Ultrathin sections of the dissected fillets were taken in a parasagittal orientation starting at the dorsal edges of muscle hemisegments using uranyl acetate and lead citrate for contrast. Samples were observed and imaged with a FEI Tecnai 12 Bio-spirit Transmission electron microscope in the Nanotechnology Innovation Center of Kansas State (NICKS). Images were prepared using the Gatan Microscopy Suite software.

Phenotypic quantification & statistical analysis

Muscle defect quantification

Six muscles within each complete thoracic hemisegment (LL1, LO1, VL1-4) were used for each type of quantification. (1) Percent muscle defects were calculated by dividing the number of abnormal muscles (regions lacking F-actin as a proxy for protein aggregation) by the total number of muscles counted in each genotype. These percentages were compiled in GraphPad 6.0 and graphically represented as dot plots. (2) A similar type of calculation (% of each type of defect/total muscles counted per genotype) was used to classify NUAK-/- phenotypes. (3) Muscle severity was quantitated for Atg8a enhancement experiments. Mild defects included long, thin regions of empty space between adjacent myofibrils or a single F-actin(-) region per muscle. Severe defects included >2 regions lacking F-actin per muscle. N≥20 for each genotype

Muscle length and sarcomere number determination

Muscle fillets at the indicated stages were stained with phalloidin. The line function in Image J was used to draw a straight line across the length of the muscle. Muscle length was determined using the measure function. The number of sarcomeres was counted after using the plot function that measures peak corresponding to the Z-disc in each sarcomere.

Pupal case axial ratio determination

Pupa of the appropriate genotype were removed from vials, oriented dorsal side up, and attached to slides using a small drop of nail polish. Images were taken with a Leica M165 FC Stereomicroscope. Length and width measurements for each pupae were performed in ImageJ using the line and measure functions. Values were put into an Excel spreadsheet and the axial ratio (length/width) was calculated for each individual. The raw data was imported into Graphpad Prism 6.0 and graphed as a box and whiskers plot. N≥20 for each genotype.

Locomotion analysis

Larval locomotion studies were performed on apple juice agar plates as described [87]. N≥20 for each genotype. Note that all control larvae (WT, mef2>+, and mef2>GFP RNAi) appear to be biphasic, where a cohort moves fast and a similar cohort moves slower. Statistical analysis by One-Way ANOVA followed by the Kruskal-Wallis test does not show a statistical difference between these genotypes.

Rescue analysis

Defective muscles for each genotype were quantitated as described above using method #1. The percentage of muscle defects was subtracted from 100% and graphed as shown. Experiments were performed at 18°C. N≥20 for each genotype.

Puncta quantification

The number of Ub(+) or p62(+) puncta in a 20 um2 area was manually counted within muscles of the indicated genotypes in regions that lacked phalloidin staining. Analysis was performed in ImageJ. N≥20 for each genotype.

Statistical analysis

Statistical analyses were performed in GraphPad 6.0. The unpaired student t-test was used to evaluate the significance between two groups. All other data sets that compared three or more unmatched groups were subjected to one-way ANOVA analysis. Data points in each graph were first analyzed for Gaussian distribution sampling. Data sets that conformed to these parameters used the Mann-Whitney test. The nonparametric Kruskal-Wallis test was used to compare three or more unmatched groups that did not conform to a Gaussian distribution. Significance values are indicated in each figure legend and in .

Quantitative RT-PCR

Transcript levels were assessed using quantitative PCR (qPCR). Total RNA was collected from three wandering L3 larvae in triplicate using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Synthesis of cDNA from 150 ng RNA (NUAK and stv RNAi) or 300 ng RNA (Hsc70-4 and Atg8a RNAi)was performed using the qScript XLT cDNA SuperMix kit (Quanta Biosciences, Beverly, MA). Dilutions of cDNA were optimized according to each primer set (1:10 to 1:100) and combined with PowerUp SYBR Green Master Mix (ThermoFisher, Waltham, MA). The following primers were used: rp49 forward 5’-GCCCAAGGGTATCGACAACA, reverse 5’-GCGCTTGTTCGATCCGTAAC; NUAK forward 5-CAGTTCCAACACAACCACGC, reverse 5’-GGATGATAAACTCCCGCGGA; stv forward 5’-GTTCCTCCAAATCAGCAGCA, reverse 5’-CAAAGTGTGAGTCGCCGAAG; Hsc70-4 forward 5’-TGG GCA AGA CTG TGA CCA AC, reverse 5’- TCC AGA CCG TAA GCG ATA GCA; Atg8a forward 5’-GGATGCCCTCTTCTTCTTTGTG, reverse 3’-CGGAGTAGGCAATGTACAGGA; cher forward 5’-GCCCTTCCAGCCACTAATAGT, reverse 5’-GCTGCCCACCTTGCTCATAT; l(2)efl/CryAB forward 5’-TTCCACCCTCAACATCGACA, reverse 5’-CATGCTTTCCCTCCACGATG; ref(2)p/p62 forward 5’- GCCCTCCCAGAATTACACCA, reverse 5’- GTTGGCCGAAGAACCCTCT. All primers were synthesized at Integrated DNA Technologies (IDT, Stokie, IL). Quantitative transcript levels were obtained using the 2-ΔΔCt method and graphed as Mean +/- SEM using GraphPad 6.0.

Gel electrophoresis and Western blotting

1D

Whole larvae of the appropriate genotype were placed into SDS sample buffer, boiled at 95°C for 3 min, homogenized to break up aggregates, boiled for an additional 10 min at 95°C, and centrifuged at 20,000xg for 10 min to pellet debris. The resulting protein samples were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), transferred to polyvinyl difluoride (PVDF) membranes (Pierce Biotechnology, Inc., Waltham, MA), and probed with rabbit anti-ref(2)p ab178440 (1:2000, Abcam, Cambridge, UK) and mouse anti-ATP5α (1:1000, Abcam, Cambridge, United Kingdom) as a loading control. Horseradish Peroxidase (HRP) conjugated secondary antibodies (1:5000–1:10000, GE Healthcare, Chicago, IL) were developed using the Prometheus ProSignal Pico detection system (Genesee Scientific, San Diego, CA) and imaged with the FluorChem M system (Protein Simple, San Jose, CA). Quantification of Western blot protein levels was performed using standard densiometric analysis functions in ImageJ.

2D

Five dissected WT or NUAK-/- larvae were homogenized in 50mM Tris + 1% SDS and centrifuged at 21,130 xg for 15 minutes. 10μL of the samples were then added to 115μL of 2D sample buffer (8M urea, 2% CHAPS, 0.05M DTT, 1X Biolyte 3–10, and 0.001% bromophenol blue). The samples were transferred to separate lanes of a BioRad Protean IEF focusing tray along with BioRad ReadyStrip IPG strips, pH 5–8, 7cm (BioRad Laboratories, Hercules, CA) and covered with mineral oil. Using a BioRad Protean IEF cell, the strips were passively rehydrated (20°C for 12 hrs) and then focused (4000V, Rapid, 15000 Vhrs). After focusing, the strips were equilibrated in DTT containing buffer (6M urea, 0.375M Tris-HCL pH = 8.8, 2% SDS, 20% glycerol, and 2% (w/v) DTT) for 15 minutes and then iodoacetamide containing buffer (6M urea, 0.375M Tris-HCL pH = 8.8, 2% SDS, 20% glycerol, and 2.5% (w/v) iodoacetamide) for 15 minutes and briefly rinsed with standard SDS-PAGE running buffer. 2nd dimension separation was achieved using 7% SDS-PAGE gels. Proteins were then transferred to PVDF membranes (Millipore, Burlington, MA) using BioRad’s Trans-Blot Turbo Transfer System (BioRad Laboratories, Hercules, CA). Membranes were blocked for one hour in Prometheus OneBlock Western-CL Blocking Buffer (Genesee Scientific, Can Diego, CA), incubated overnight in rabbit anti-Fil (1:5000, see ) in the same blocking buffer, washed, blocked for 30 minutes, incubated for 2 hrs at room temperature with 1:10,000 ECL rabbit HRP secondary (GE Healthcare Chicago, IL) in the blocking buffer, washed, and developed with Prometheus ProSignal Pico substrate (Genesee Scientific, Can Diego, CA). Images were obtain using a Protein Simple FluorChem M system.

Soluble/Insoluble fractionation

Muscle carcasses from ten dissected WT or NUAK-/- larvae were homogenized in 100μL ice cold RIPA buffer (50mM Tris pH = 8, 150mM NaCl, 2mM EDTA, 1% tritonX, 0.1% SDS, 1%NaDexoxycholate, and Halt Protease Inhibitors Cocktail (ThermoFisher, Waltham, MA). The homogenate was centrifuged at 21,130 xg for 10 minutes at 4°C. The supernatant (RIPA buffer soluble sample) was transferred to a clean tube, 10μL were removed for protein determination by BCA assay, and 100μL SDS-PAGE sample buffer (62.5mM Tris pH = 6.8, 25% glycerol, 2% SDS, 0.01% Bromophenol Blue, 5% B-mercaptoethanol) was added. The pellet from the RIPA buffer homogenization was washed twice with 500μL phosphate buffered saline containing Halt Protease Inhibitor Cocktail (ThermoFisher, Waltham, MA). 100μL of room temperature Urea buffer (9M Urea, 50mM Tris pH = 8, 1% CHAPS, and halt protease inhibitors) was added and the pellet was re-homogenized. The resulting mixture was centrifuged at 21,130 xg for 10 minutes at 4°C. The supernatant (Urea buffer soluble sample) was transferred to a clean tube, 10μL were removed for a BCA assay, and 100μL SDS-PAGE sample buffer was added. The remaining pellet was washed once with 1mL phosphate buffered saline containing Halt Protease Inhibitors and then re-homogenized in 100μL SDS-PAGE sample buffer (SDS buffer soluble sample). For the RIPA and Urea soluble samples, protein concentration was determined using Pierce BCA Protein Assay kit (ThermoFisher, Waltham, MA). All three samples were boiled 5–10 minutes and centrifuged before loading to a SDS-PAGE gel. For RIPA and Urea soluble samples, 10μg of total protein was loaded; for SDS buffer samples, 10–15μL was loaded. Western blotting was performed as described for 1D and 2Dgels using rabbit anti-Fil (1:5000) and rabbit anti-Ubi-K63 (1:1000, Enzo Life Sciences, Farmingdale, NY).

Yeast 2-hybrid screen and verification

Screen

Y2H screens were performed by Hybrigenics Services. The coding sequence of the full-length Drosophila NUAK/CG43143 (isoform D) was PCR-amplified and cloned in frame with the Gal4 DNA binding domain (DBD) into plasmid pB66 as a C-terminal fusion to Gal4 (Gal4-bait fusion) (Fromont-Racine et al., 1997). Drosophila Stv/CG10745 was also PCR-amplified and cloned in frame with the DBD as a C-terminal fusion to Gal4 into plasmid pB35. These NUAK-DBD or Stv-DBD bait proteins were independently used to screen a Drosophila L3 larval library at 2.0 mM or 10.0 mM 3AT respectively. 57.5 and 52.9 million interactions were analyzed for NUAK and STV, respectively. All interacting prey fragments were sequenced.

Verification

For 1 x 1 interaction assays with NUAK, the prey fragment corresponding to amino acids 322–516 of Stv were cloned in frame with the Gal4 activation domain (AD) into plasmid pP6, derived from the original pGADGH plasmid (Bartel et al. 1993). Bait and prey constructs were transformed in the yeast haploid cells CG1945 (mata) and YHGX13 (Y187ade2-101::loxP-kanMX-loxP, matα), respectively. The diploid yeast cells were obtained using a mating protocol with both yeast strains (Fromont-Racine et al., 1997). These assays are based on the HIS3 reporter gene (growth assay without histidine). As negative controls, the bait plasmid was tested in the presence of empty prey vector (pP7) and all prey plasmids were tested with the empty bait vector (pB66). Controls and interactions were tested in the form of streaks of three independent yeast clones for each control and interaction on DO-2 and DO-3 selective media. The DO-2 selective medium lacking tryptophan and leucine was used as a growth control and to verify the presence of the bait and prey plasmids. The DO-3 selective medium without tryptophan, leucine, and histidine selects for the interaction between bait and prey.

Raw data and statistics summary.

Graph type, n values, statistical tests and p-values for all quantitative analysis. (DOCX) Click here for additional data file.

The l(3)17289 mutation maps to CG41343.

(A) Deficiency mapping narrowed down the l(3) 17289 mutation to Df(3R)BSC479. This deficiency removes ten genes. (B) RT-PCR and Sanger sequencing of CG43143 revealed a C>T change that results in a stop codon. (TIF) Click here for additional data file.

Induction of NUAK RNAi causes muscle degeneration.

(A-B’) L3 muscle fillets stained with phalloidin after knockdown of NUAK using two independent UAS-RNAi insertions (UAS-NUAK or UAS-NUAK ). (A-B’) 4x magnification (A,B) or 10x view of one hemisegment (A’,B’) shows thinner (carets) or detached (arrowhead) muscles. (A”,B”) 20x image of a representative VL3 muscle show areas lacking F-actin (white dotted outline). (C) qPCR verifies that NUAK transcript levels are reduced ~50% after induction of either UAS-NUAK or UAS-NUAK using the ubiquitous daughterless (da)-Gal4 driver. (D) Box and whisker plot depicting axial ratios of pupal length upon ubiquitous knockdown of NUAK RNAi with da-Gal4. (E,F) Whole mount L1 larval muscles visualized with MHC-GFP. Thinner (white carets) or altered muscle pattern (white arrowhead) is observed upon loss of NUAK. Mean +/- SEM (**, p<0.01; ***, p<0.005; ****, p<0.001). (TIF) Click here for additional data file.

Tissue degeneration occurs upon a decrease of NUAK in muscle, but not neurons.

(A-D) L3 muscles within a single hemisegment stained with phalloidin. (A) Expression of the mef2 driver alone shows no phenotype. (B) mef2-driven NUAK RNAi results in morphological muscle defects. (C,D) Neither the neuronal driver C155 alone (C) or inducing NUAK RNAi (D) causes muscle phenotypes. (E) Scatter plot shows that muscle defects are only apparent upon NUAK RNAi induction in muscle, but not neuronal tissue. (F) Scatter plot of larval locomotor ability upon muscle (mef2) or neuronal (C155) RNAi knockdown of NUAK. Larvae were transferred from 25°C to 29°C after hatching. Mean +/- SEM (*, p<0.05; ****, p<0.001; n.s., not significant). (TIF) Click here for additional data file.

Fil does not accumulate in torn muscles.

(A-B”) Intentionally torn L3 muscles stained for F-actin (green) do not accumulate Fil protein (purple, asterisk). (C,D’) NUAK-/- with regions devoid of F-actin (green, white arrow) have an intact basement membrane visualized by Perlecan (purple). (TIF) Click here for additional data file.

Two independent stv RNAi lines show muscle morphology defects.

(A-B’) 10x or 20 x images of a single hemisegment of the L3 musculature stained with phalloidin (green). Expression of both stv RNAi insertions in muscle show regions that where F-actin is excluded (* in A,B; white dotted lines in A’,B’). (C) Both the UAS-stv or UAS-stv RNAi lines effectively decrease stv mRNA levels as assayed by qPCR. Mean +/- SEM (**, p<0.01). (TIF) Click here for additional data file.

Genetic interactions with CASA pathway components.

(A,B) One hemisegment of the L3 musculature stained with phalloidin. Defects caused by knockdown of NUAK RNAi (A) can be rescued upon re-introduction of NUAK cDNA in muscle tissue. (C) Bar graph showing NUAK rescue results. NUAK is capable of restoring muscle defects due to loss of NUAK, but not Stv, Hsc70-4, or Atg8a. (D,E) Scatter plots of genetic interactions with NUAK (D) or stv (E). Mean +/- SEM (*, p<0.05; ****, p<0.001). (TIF) Click here for additional data file.

Hsc70-4 and Atg8a muscle phenotypes upon RNAi knockdown.

(A,C) F-actin labeled muscles in two hemisegments of the L3 musculature. (A) Nearly all muscles of the genotype mef2>Hsc70-4 show abnormal morphology (*). (A’) Regions devoid of F-actin are outlined (white dashed lines). (B) Bar graph shows a decrease in Hsc70-4 mRNA levels driven with mef2-Gal4. (C) RNAi knockdown of Atg8a mRNA affects muscles to a lesser extent. (C’) The predominant phenotype is the presence of dark regions, indicative of protein aggregation. (D) Bar graph illustrating that the UAS-Atg8a RNAi insertion effectively reduces transcript levels. Mean +/- SEM (*, p<0.05; **, p<0.01). (TIF) Click here for additional data file.

p62 transcripts are increased in NUAK-/- and stv-/-.

Bar graphs showing the indicated transcripts in NUAK-/- or stv-/-. cher, CryAB, Hsc70-4, and Atg8a mRNA levels are not altered upon loss of NUAK or Stv (left panel). stv transcript levels are mildly increased in NUAK mutants, but NUAK transcripts do not change upon loss of Stv (middle panel). p62 mRNA levels are much higher in both NUAK and stv mutants (right panel). Mean +/- SEM (*, p<0.05; **, p<0.01; n.s., not significant). (TIF) Click here for additional data file.

Characterization of Fil antisera.

(A-B”) Anti-Fil (green) and F-actin (purple) staining of L3 muscles VL3 and VL4 in control (mef2>+) or upon a decrease in cher mRNA levels (mef2>cher). The striated pattern of Fil immunostaining (A,A”) is blunted upon targeted induction of cher RNAi in muscle tissue (B, B”). (C) Western blot showing a decrease in the 90 kD form of Fil after knockdown of cher transcripts. (TIF) Click here for additional data file.
  87 in total

Review 1.  Chaperone-assisted degradation: multiple paths to destruction.

Authors:  Nadja Kettern; Michael Dreiseidler; Riga Tawo; Jörg Höhfeld
Journal:  Biol Chem       Date:  2010-05       Impact factor: 3.915

2.  Optimization of wrMTrck to monitor Drosophila larval locomotor activity.

Authors:  David S Brooks; Kumar Vishal; Jessica Kawakami; Samuel Bouyain; Erika R Geisbrecht
Journal:  J Insect Physiol       Date:  2016-07-16       Impact factor: 2.354

3.  The Role of the UNC-82 Protein Kinase in Organizing Myosin Filaments in Striated Muscle of Caenorhabditis elegans.

Authors:  NaTasha R Schiller; Christopher D Duchesneau; Latrisha S Lane; April R Reedy; Emily R Manzon; Pamela E Hoppe
Journal:  Genetics       Date:  2016-12-30       Impact factor: 4.562

Review 4.  Chaperones in autophagy.

Authors:  Susmita Kaushik; Ana Maria Cuervo
Journal:  Pharmacol Res       Date:  2012-10-08       Impact factor: 7.658

5.  The cochaperone BAG3 coordinates protein synthesis and autophagy under mechanical strain through spatial regulation of mTORC1.

Authors:  Barbara Kathage; Sebastian Gehlert; Anna Ulbricht; Laura Lüdecke; Victor E Tapia; Zacharias Orfanos; Daniela Wenzel; Wilhelm Bloch; Rudolf Volkmer; Bernd K Fleischmann; Dieter O Fürst; Jörg Höhfeld
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2016-10-15       Impact factor: 4.739

Review 6.  The role of αB-crystallin in skeletal and cardiac muscle tissues.

Authors:  Ivan Dimauro; Ambra Antonioni; Neri Mercatelli; Daniela Caporossi
Journal:  Cell Stress Chaperones       Date:  2017-11-30       Impact factor: 3.667

7.  A genetic screen identifies new regulators of steroid-triggered programmed cell death in Drosophila.

Authors:  Lei Wang; Janelle Evans; Hillary K Andrews; Robert B Beckstead; Carl S Thummel; Arash Bashirullah
Journal:  Genetics       Date:  2008-08-30       Impact factor: 4.562

8.  Protein aggregation and degradation mechanisms in neurodegenerative diseases.

Authors:  Mari Takalo; Antero Salminen; Hilkka Soininen; Mikko Hiltunen; Annakaisa Haapasalo
Journal:  Am J Neurodegener Dis       Date:  2013-03-08

Review 9.  Role of the mammalian ATG8/LC3 family in autophagy: differential and compensatory roles in the spatiotemporal regulation of autophagy.

Authors:  You-Kyung Lee; Jin-A Lee
Journal:  BMB Rep       Date:  2016-08       Impact factor: 4.778

10.  Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).

Authors:  Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier
Journal:  Autophagy       Date:  2016       Impact factor: 16.016

View more
  4 in total

1.  Costameric integrin and sarcoglycan protein levels are altered in a Drosophila model for Limb-girdle muscular dystrophy type 2H.

Authors:  Simranjot Bawa; Samantha Gameros; Kenny Baumann; David S Brooks; Joseph A Kollhoff; Michal Zolkiewski; Andrea David Re Cecconi; Nicolò Panini; Massimo Russo; Rosanna Piccirillo; David K Johnson; Maithri M Kashipathy; Kevin P Battaile; Scott Lovell; Samuel E A Bouyain; Jessica Kawakami; Erika R Geisbrecht
Journal:  Mol Biol Cell       Date:  2020-12-09       Impact factor: 4.138

2.  Drosophila p38 MAPK interacts with BAG-3/starvin to regulate age-dependent protein homeostasis.

Authors:  Sarah M Ryan; Michael Almassey; Amelia M Burch; Gia Ngo; Julia M Martin; David Myers; Devin Compton; Shira Archie; Megan Cross; Lauren Naeger; Ashley Salzman; Alyssa Virola-Iarussi; Scott A Barbee; Nathan T Mortimer; Subhabrata Sanyal; Alysia D Vrailas-Mortimer
Journal:  Aging Cell       Date:  2021-10-21       Impact factor: 11.005

3.  A large-scale transgenic RNAi screen identifies transcription factors that modulate myofiber size in Drosophila.

Authors:  Flavia A Graca; Natalie Sheffield; Melissa Puppa; David Finkelstein; Liam C Hunt; Fabio Demontis
Journal:  PLoS Genet       Date:  2021-11-15       Impact factor: 5.917

4.  Gene expression profiling of NUAK kinase overexpression in Drosophila larval muscle development.

Authors:  David Brooks; Erika R Geisbrecht
Journal:  Data Brief       Date:  2022-07-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.